BIOFRONTERA AG (B8FK.DE) Stock Overview
FRA:B8FK - DE000A4BGGM7 - Common Stock
B8FK.DE Key Statistics, Chart & Performance
The current stock price of B8FK.DE is 2.55 EUR. In the past month the price decreased by -5.56%. In the past year, price increased by 2.82%.
B8FK.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 45.04 | 588.70B | ||
| 1LLY.MI | ELI LILLY & CO | 44.97 | 587.85B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.48 | 432.52B | ||
| JNJ.DE | JOHNSON & JOHNSON | 17.85 | 367.61B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 17.65 | 365.97B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.75 | 250.06B | ||
| NOT.DE | NOVARTIS AG-REG | 14.84 | 214.61B | ||
| NOV.DE | NOVO NORDISK A/S-B | 14.08 | 209.02B | ||
| SAN.PA | SANOFI | 10.53 | 193.90B | ||
| SNW.DE | SANOFI | 10.53 | 193.90B | ||
| 1SAN.MI | SANOFI | 10.52 | 193.75B | ||
| 6MK.DE | MERCK & CO. INC. | 10.96 | 180.09B |
Related stock screener links
About B8FK.DE
Company Profile
Biofrontera AG engages in the research, development, and marketing of dermatological products. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 87 full-time employees. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Company Info
BIOFRONTERA AG
Hemmelrather Weg 201
Leverkusen NORDRHEIN-WESTFALEN DE
Employees: 87
Phone: 49214876320
BIOFRONTERA AG / B8FK.DE FAQ
What is the stock price of BIOFRONTERA AG today?
The current stock price of B8FK.DE is 2.55 EUR.
What is the ticker symbol for BIOFRONTERA AG stock?
The exchange symbol of BIOFRONTERA AG is B8FK and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is B8FK.DE stock listed?
B8FK.DE stock is listed on the Deutsche Boerse Ag exchange.
What is BIOFRONTERA AG worth?
BIOFRONTERA AG (B8FK.DE) has a market capitalization of 15.50M EUR. This makes B8FK.DE a Nano Cap stock.
How many employees does BIOFRONTERA AG have?
BIOFRONTERA AG (B8FK.DE) currently has 87 employees.
What are the support and resistance levels for BIOFRONTERA AG (B8FK.DE) stock?
BIOFRONTERA AG (B8FK.DE) has a support level at 2.44 and a resistance level at 2.77. Check the full technical report for a detailed analysis of B8FK.DE support and resistance levels.
Is BIOFRONTERA AG (B8FK.DE) expected to grow?
The Revenue of BIOFRONTERA AG (B8FK.DE) is expected to grow by 22.18% in the next year. Check the estimates tab for more information on the B8FK.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOFRONTERA AG (B8FK.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of B8FK.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of B8FK.DE, evaluating the profitability, health, valuation and growth aspects
- BIOFRONTERA AG (B8FK.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOFRONTERA AG (B8FK.DE) Sales and EPS estimates to see what analysts future expectations are.
- BIOFRONTERA AG (B8FK.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOFRONTERA AG (B8FK.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOFRONTERA AG (B8FK.DE) Stock Chart to make your own analysis
- BIOFRONTERA AG (B8FK.DE) Latest news and press-releases to stay up to date.
Does BIOFRONTERA AG (B8FK.DE) stock pay dividends?
B8FK.DE does not pay a dividend.
When does BIOFRONTERA AG (B8FK.DE) report earnings?
BIOFRONTERA AG (B8FK.DE) will report earnings on 2025-09-30.
What is the Price/Earnings (PE) ratio of BIOFRONTERA AG (B8FK.DE)?
BIOFRONTERA AG (B8FK.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
B8FK.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to B8FK.DE. When comparing the yearly performance of all stocks, B8FK.DE turns out to be only a medium performer in the overall market: it outperformed 57.6% of all stocks.
B8FK.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to B8FK.DE. B8FK.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
B8FK.DE Financial Highlights
Over the last trailing twelve months B8FK.DE reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -915.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.67% | ||
| ROE | -23.07% | ||
| Debt/Equity | 0.02 |
B8FK.DE Forecast & Estimates
For the next year, analysts expect an EPS growth of 124.55% and a revenue growth 22.18% for B8FK.DE